Shares of Valeant Pharmaceuticals fell nearly 8 percent Wednesday after a report said the company’s talks to sell its stomach-drug unit to Japan’s Takeda Pharmaceutical have fallen apart.
Takeda’s shares were down about 1 percent in Tokyo trading Wednesday after the report.
Earlier this month, Takeda was rumored to be in discussions with Valeant to acquire Salix Pharmaceuticals for about $10 billion. The talks have ended amid a disagreement over the price and other matters, CNBC confirmed. Dow Jones was the first to report the news.
